Atrial Fibrillation Documentation: AFib Notes, Anticoagulation & Follow-Up
Dr. Medeline Yost
Chief Medical Officer, Augustun
Published July 2, 2026
Updated July 2, 2026
On this page
Atrial fibrillation is one of the most common arrhythmias cardiologists manage — and one of the most documentation-intensive. A single AFib visit may include symptom review, rhythm vs. rate control strategy, anticoagulation shared decision-making, CHA₂DS₂-VASc and HAS-BLED discussion, medication reconciliation, and planning for cardioversion, ablation, or device monitoring.
AFib notes fail audits when they only say "AFib, continue meds." Payers and quality reviewers want evidence that stroke risk was assessed, bleeding risk was considered, anticoagulation rationale was documented, and the patient received appropriate counseling. The note should also capture whether AFib is paroxysmal, persistent, or permanent — and whether the current visit represents a change in clinical status.
This guide focuses specifically on AFib documentation — complementing our general cardiac SOAP note examples and cardiology consult note guide without repeating their content.
What Every AFib Note Should Capture
| Element | Why it matters |
|---|---|
| AFib classification | Paroxysmal, persistent, long-standing persistent, or permanent — affects management and coding. |
| Symptom burden | Palpitations, dyspnea, fatigue, exercise tolerance, syncope — guides rate vs. rhythm strategy. |
| Rhythm assessment | Current rhythm, last episode timing, Holter/monitor/Zio results if reviewed. |
| Rate control status | Resting HR, beta-blocker or calcium channel blocker dose, target rate. |
| Stroke risk | CHA₂DS₂-VASc score with component factors documented. |
| Bleeding risk | HAS-BLED or clinical bleeding history when anticoagulation is discussed. |
| Anticoagulation decision | Agent, dose, indication, shared decision-making, patient preferences. |
| Plan | Labs (INR for warfarin, renal function for DOACs), follow-up, procedure planning, precautions. |
Documenting Anticoagulation Shared Decision-Making
Anticoagulation documentation is where AFib notes are most often challenged. The note should show that stroke prevention was discussed, not assumed. Document the CHA₂DS₂-VASc score, bleeding concerns, patient preferences, and why a specific agent was chosen or declined. If the patient declines anticoagulation despite elevated stroke risk, document the discussion and alternatives considered.
- Record renal function when prescribing DOACs.
- Note drug interactions (especially with antiarrhythmics and amiodarone).
- Document fall risk without using it as an automatic contraindication without discussion.
- Include hold parameters for procedures and bleeding events.
- Provide clear bleeding precautions and when to seek care.
Example SOAP Note: Newly Diagnosed AFib
AFib SOAP Note — New Diagnosis
- Subjective
- 68-year-old reports 3 weeks of intermittent palpitations and reduced exercise tolerance. No syncope or chest pain. ECG in clinic today showed atrial fibrillation. Patient concerned about stroke risk and medication side effects.
- Objective
- BP 132/78, HR 98 irregular. Exam: irregularly irregular rhythm, no murmur, lungs clear, no edema. ECG: atrial fibrillation, ventricular rate 98, no acute ischemic changes. TSH and BMP reviewed — within acceptable limits.
- Assessment
- New-onset atrial fibrillation, likely paroxysmal pattern. CHA₂DS₂-VASc score 3 (age, HTN, DM). Elevated stroke risk discussed.
- Plan
- Initiate rate control with beta-blocker. Start apixaban 5 mg BID after shared decision-making regarding stroke prevention — patient understands benefits and bleeding risks. Order TTE. Discuss rhythm control options if symptoms persist. Ambulatory monitor to assess AF burden. RTC 4 weeks with labs. ED precautions for syncope, sustained rapid palpitations, chest pain, or neurologic symptoms.
Example SOAP Note: AFib on Anticoagulation Follow-Up
AFib Follow-Up — Stable on DOAC
- Subjective
- 72-year-old with persistent AFib returns for follow-up. Reports improved symptoms on current rate-control regimen. No bleeding, bruising, or syncope. Compliant with apixaban.
- Objective
- BP 128/74, HR 72 irregular. Exam stable. Creatinine unchanged. No signs of bleeding.
- Assessment
- Persistent atrial fibrillation, rate-controlled, on anticoagulation for stroke prevention (CHA₂DS₂-VASc 4). Clinically stable today.
- Plan
- Continue current rate-control and apixaban regimen. Reinforce adherence and bleeding precautions. Annual renal function monitoring. Revisit rhythm control strategy if symptom burden increases. RTC 6 months or sooner for palpitations, bleeding, or neurologic symptoms.
AFib Documentation and AI Scribes
AFib visits involve repetitive but critical elements — risk scores, anticoagulation counseling, and rhythm strategy — that are easy to omit when charting late. A specialty-aware AI scribe for cardiology can draft structured notes that surface CHA₂DS₂-VASc components and anticoagulation discussions from the encounter, but the cardiologist must verify scores, doses, and clinical reasoning.
AI-Powered · HIPAA-Ready
Document AFib visits with less charting time
[Augustun for cardiology](/specialties/cardiology) drafts AFib-aware SOAP notes, progress notes, and consult letters from patient conversations — preserving rhythm, risk, and anticoagulation detail for EHR-ready review.
No credit card required.
Frequently asked questions
Should CHA₂DS₂-VASc be documented at every AFib visit?
Document stroke risk assessment at initial diagnosis and whenever anticoagulation is initiated, changed, or discontinued. At follow-up, note that risk remains elevated or reference the prior assessment if unchanged.
How do you document rate vs. rhythm control strategy?
State the chosen strategy and the clinical rationale — symptom burden, AF type, comorbidities, prior failed therapies, and patient preference. Update the note when strategy changes.
What AFib details are commonly missed in notes?
AFib type (paroxysmal vs. persistent), anticoagulation shared decision-making, bleeding counseling, renal function for DOACs, and clear return precautions for syncope or neurologic symptoms.
AI-Powered · HIPAA-Ready
Spend more time with patients, not paperwork.
Augustun transforms ambient speech into accurate notes — finished before your next session.
No credit card required.
Dr. Medeline Yost
Chief Medical Officer, Augustun
Dr. Medeline Yost is an Internal Medicine physician and an emerging leader in clinical innovation. As Chief Medical Officer at Augustun, she helps shape AI-powered tools that streamline clinical documentation and support physicians in delivering higher-quality care. Her professional interests include medical education, workflow redesign, and the responsible use of AI in healthcare — building systems that let clinicians spend more time with patients and less on administrative tasks.